Press release


10/01/2014
SOM Biotech announces Orphan Drug Designation in US for SOM0226, a compound for the treatment of Transthyretin Amyloidosis (ATTR).
The US FDA assigned Orphan Drug Designation to SOM Biotech SL for SOM0226 for the treatment of Transthyretin Amyloidosis (ATTR). This compound is indicated for all variants of the disease: Familial Amyloid Polyneuropathy (FAP), Familial Amyloid Cardiomyopathy (FAC), Senile Systemic Amyloidosis (SSA) and CNS Selective Amyloidosis (CNSA).
You will find the link to Press Release below.
 
 
 
 
 
Permalink  
 
Developed by Web4Bio